This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Stretta In Reflux Uncontrolled by IPP (SIRUP)

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Nantes University Hospital
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT01682265
First received: September 5, 2012
Last updated: October 4, 2016
Last verified: October 2016
  Purpose
The aim of the study is to compare the Stretta procedure and the Sham procedure efficiency 6months post-procedure in reflux uncontrolled by intake of Inhibitors of Protons Pump (IPP) patients.

Condition Intervention
Gastroesophageal Reflux Disease Other: Stretta procedure Other: Sham procedure

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Stretta In Reflux Uncontrolled by Intake of Inhibitors of Protons Pump (IPP).- The SIRUP Trial- Multicentric, Randomized, Double Blind, Prospective Study

Resource links provided by NLM:


Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • Efficiency of the treatment 6 months post-procedure [ Time Frame: 6 months ]
    Evaluate the efficiency of the treatment 6 months post-procedure according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 24


Secondary Outcome Measures:
  • Effects on digestive symptoms [ Time Frame: 6 months ]
    Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 6 months)

  • Effects on digestive symptoms [ Time Frame: 1 year ]
    Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 12 months)

  • Necessity of IPP treatment [ Time Frame: 6 months ]
    Compare Stretta and sham procedure according to necessity of IPP treatment

  • necessity of IPP treatment [ Time Frame: 1 year ]
    Compare Stretta and sham procedure according to necessity of IPP treatment

  • Tolerance [ Time Frame: 6 months ]
    Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 24.

  • Tolerance [ Time Frame: 1 year ]
    Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 48.

  • Quality of live [ Time Frame: 6 months ]
    Compare Stretta and sham procedure according to Quality of life (use of quality of life questionaries)

  • Quality of life [ Time Frame: 1 year ]
    Compare Stretta and sham procedure according to Quality of life

  • pH-impedancemetry predictive factors [ Time Frame: At Inclusion ]
    pH-impedancemetry will be realized at clinical trial start, when patient is under PPI intake to determine pH-impedancemetry predictive factors for positive response to stretta method. Acid and non acid exposition of the esophagus will be measured as well as the SAP (Symptom Association Probability) which corresponds to the probability of association between symptoms felt by the patient during the pH-impedancemetry and episodes of acid or non acid reflux.

  • Efficiency [ Time Frame: 1 year ]
    Evaluate efficiency of the stretta procedure in patients unsatisfied after the sham procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48

  • Efficiency [ Time Frame: 1 year ]
    Evaluate efficiency of the 2nd stretta procedure in patients unsatisfied after the 1st stretta procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48


Estimated Enrollment: 60
Study Start Date: March 2012
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stretta procedure

Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.

Control visits will then take place until Month 6. At this visit endoscopic control will take place.

Other: Stretta procedure
Other Name: Radiofrequency of esophagus
Sham Comparator: Sham procedure

Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.

Control visits will then take place until Month 6. At this visit endoscopic control will take place.

Other: Sham procedure
No radiofrequency delivered

Detailed Description:

The study is over a period of 1 year. After checking eligibility, the patient will be randomised in double blind : stretta procedure /sham procedure. Control visits will take place after 4 weeks (on site), 8 weeks (by phone), 12 weeks (by phone), 18 weeks(on site) and 24 weeks(on site).During the 24 weeks visit, the therapeutic success will be evaluated.

In case of success, endoscopic control will be performed and the patient will come back on site at week 36 and 48 (end of study). In case of therapeutic failure, the stretta procedure will be proposed to the patient without breaking the blind for the 1st procedure. The procedure will be scheduled between week 24 and week 27. The patient will come back for a visit on site at weeks 31, 36 and 48 (end of visit)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 ans
  • Severe or moderate heartburn (at least 3 heartburn times per week), persistent under treatment with IPP

Exclusion Criteria:

  • Recent oeso-gastro-duodenal endoscopy(< 3 months)
  • Oesophagitis > grade A
  • Endobrachyoesophagus > C0M1
  • Hiatal Hernia > 2 cm
  • Symptoms insufficiently relieved with continued intake of IPP or with intake of IPP according to needs
  • Predominant symptom of Gastrooesophageal reflux disease other than heartburn
  • Patients contra-indicated for radiofrequency technique
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01682265

Contacts
Contact: Stanislas Bruley des Varannes, Professor +33 2.40.08.33.06 stanilas.bruleydesvarannes@chu-nantes.fr

Locations
France
Nantes Universitary Hospital Recruiting
Nantes, Loire Atlantique, France, 44093
Contact: Stanislas Bruley des Varannes, Professor         
Principal Investigator: Stanislas Bruley des Varannes, Professor         
Bordeaux Universitary Hospital Recruiting
Bordeaux, France
Contact: Franck Zerbib, Professor    +33 5 56 79 58 06    frank.zerbib@chu-bordeaux.fr   
Principal Investigator: Franck Zerbib, Professor         
Brest universitary hospital Recruiting
Brest, France, 29200
Contact: Franck CHOLET, Doctor       franck.cholet@chu-brest.fr   
Principal Investigator: Franck CHOLET, PH         
APHP - Louis Mourier hospital Recruiting
Colombes, France, 92700
Contact: benoit Coffin, Professor       benoit.coffin@aphp.fr   
Principal Investigator: Benoit Coffin         
Lyon Universitary Hospital Recruiting
Lyon, France, 69000
Contact: Thierry Ponchon, Professor    +33 472110149    thierry.ponchon@chu-lyon.fr   
Principal Investigator: Thierry Ponchon, Professor         
Rouen Universitary Hospital Recruiting
Rouen, France, 76000
Contact: Philippe Ducrotte, Professor    +33 2 32 88 81 01    philippe.ducrotte@chu-rouen.fr   
Principal Investigator: Philippe Ducrotte, Professor         
Sponsors and Collaborators
Nantes University Hospital
Investigators
Principal Investigator: Stanislas Bruley des Varannes, Professor Nantes Universitary Hospital
Principal Investigator: Philippe Ducrotte, Professor Rouen Universitary Hospital
Principal Investigator: Thierry Ponchon, Professor Lyon Universitary Hospital
Principal Investigator: Franck Zerbib, Professor Bordeaux Universitary Hospital
Principal Investigator: Franck Cholet, Doctor Brest Universitary hospital
Principal Investigator: Benoit Coffin, Professor APHP-Louis Mourier hospital
  More Information

Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT01682265     History of Changes
Other Study ID Numbers: BRD/11/06-Q
Study First Received: September 5, 2012
Last Updated: October 4, 2016

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 23, 2017